Title
Category
Credits
Event date
Cost
  • Digital health
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore a variety of digital health modalities and help learners understand the broad landscape of digital medicine and beyond. It will discuss the potential for these modalities to enhance health care delivery, offer increased access to health care and ultimately improve patient outcomes.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will discuss emerging therapies for DMD and the importance of incorporating a personalized interprofessional care plan, along with the role of health disparities and how these impacts access to care and outcomes for these individuals.
  • Intellectual and developmental disabilities
  • 2.00 ACPE - Pharmacists
  • 2.00 ACPE - Pharmacy Technicians
  • 2.00 AMA - Physicians
  • 2.00 ANCC - Nurses
  • 2.00 APA - Psychologists
  • 2.00 Attendance - General Attendance
  • 2.00 CCMC - General - Case Managers
  • 2.00 CDR - Dietitians
  • 2.00 COPE - Optometrists
  • 2.00 ASWB - Social Workers
$0.00
This activity will provide learners with an overview of clinical considerations in adults with IDD and improve communication skills and practices that can better guide treatment choices to address the specific needs of these individuals. Learners will take a closer look at existing bias, stigma and discrimination toward these individuals and learn strategies to address these issues in practice. Lastly, the value of improved interprofessional team collaboration between health care professionals (HCPs), caregivers and direct support professionals will be discussed.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of leukodystrophies, including current clinical trials. It will also share insights and perspectives from individuals and their family/caregiver(s) and provide strategies to support their well-being.
  • Disease management
  • Older adults
  • Oncology
  • Transplantation
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will provide an overview of geriatric and frailty assessment tools that can assist in guiding cancer- and transplant-related decision making through the risk stratification of older individuals before therapy is initiated. Data surrounding the relationship among increased age, geriatric- and frailty-assessment results, and disease outcomes will also be explored. Key considerations in how to best incorporate these sometimes time-intensive assessments into practice will be outlined, along with discussion of how interprofessional collaboration among members of the health care team in the creation of care plans can facilitate quality care.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of Pompe disease and other LSDs, including current clinical trials. It will also share insights and perspectives from and provide strategies to support the well-being of both the individual and their family/caregiver(s) and highlight the role of the interprofessional team in evaluating and improving care for patients with these conditions.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore the recent advances in the diagnosis and treatment of achondroplasia and other causes of disproportionate short stature. It will also share the importance of the interprofessional team to provide insights, perspectives and strategies to support the well-being of both the individual and their family/caregiver(s).
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This session examines the cost of development and growth of these pharmaceuticals and details the specific role that specialty pharmacy plays in making these products accessible. The high costs of therapies and patient and medication management are also discussed along with the role and value of drug benefit programs.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of KLA and other lymphatic conditions, including current clinical trials. It will also share insights and perspectives from and provide strategies to support the well-being of both the individual and their family/caregiver(s).
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity examines current data about chronic kidney disease (CKD), including its health outcomes and relationships with cardiovascular and metabolic disease. Treatment regimens aimed at delaying progression and their outcomes are reviewed, along with current knowledge regarding the pathophysiologic and genetic basis of this disease. Areas of emerging interest in research on potential new treatments targeting the causes of CKD are discussed, including genomic analysis, and their relevance to clinical care.

Pages